Stationery maker’s diverse bets deliver growth, but 60x earnings multiple leaves little room for slip-ups
DOMS Industries Ltd. isn’t reinventing the wheel—it’s just making better pencils, pens, and now premium bags. The third-quarter performance exemplifies the company’s steady-as-she-goes approach: consolidated revenue climbed 18% year-over-year to Rs5.92 billion, EBITDA grew 18%, and profit after tax expanded 13%. For a stationery company navigating everything from art supplies to baby diapers, that’s remarkably consistent execution.
“The company continued with its good results sequence,” Nuvama noted, with management conservatively guiding for 18-20% top-line growth in fiscal 2026. Through nine months, DOMS has actually outperformed, delivering 22.7% revenue growth while maintaining EBITDA margins at 17.5%—the high end of its guided 16.5-17.5% range.
The Growth Cocktail: Mix Matters
Dig beneath the headline numbers and DOMS’ strategy crystallizes: diversify the product basket while riding secular trends in education and premiumisation. Its segmental breakdown reveals where the action is. Office supplies surged 58% year-over-year, kits and combos jumped 31%, and hobby and craft products exploded 255% off a low base. Even scholastic art materials—the bread-and-butter segment—managed 18% growth after a tepid first half.
Not everything sparkled. Paper stationery declined 11% and scholastic stationery barely budged at 2% growth. But that’s precisely why DOMS keeps expanding: when one category stalls, another accelerates. “If we combine performance of Scholastic art material, Scholastic stationery, and Kits & Combos, then sales growth was better at 11% versus mid-single-digit growth in the first half,” JM Financial observed.
Geography tells a similar story. Domestic business surged 19% while exports grew a more modest 9%, hampered by US tariff challenges that Nuvama flagged. For now, India remains the growth engine.
Uniclan and Winter’s Gift
The Uniclan Healthcare acquisition—DOMS’ foray into baby hygiene products—is paying dividends faster than skeptics expected. The subsidiary contributed Rs651 million to third-quarter revenue, benefiting from seasonally strong winter demand for diapers. More impressively, Uniclan’s EBITDA margins improved to 12% from 10.2% a year earlier, with the quarter accounting for 30% of annual revenues.
“DOMS continues to focus on ramping up the baby hygiene segment by developing a robust distribution network,” Nuvama noted. It’s early days, but the hygiene business grew 28% year-over-year according to JM Financial, outpacing the core stationery operation’s 17% growth.
Margin Tightrope
EBITDA margins held steady at 17.5% year-over-year, but the components shifted. Favorable raw material pricing provided tailwinds, though Nuvama noted prices ticked up after quarter-end. The real margin pressure came from employee stock option expenses and fixed cost absorption at the upcoming 44-acre facility.
JM Financial highlighted gross margin expansion of 67 basis points to 44.2%, but elevated staff costs (up 21% year-over-year) and other overheads (up 23%) absorbed much of the benefit. For a company investing heavily in capacity and talent, these are growth pains worth enduring—but they constrain near-term margin expansion.
Higher depreciation offset lower interest expenses, which explains why profit growth of 13% lagged revenue and EBITDA gains. JM Financial noted reported PAT came “tad below” estimates due to lower-than-expected other income, primarily from cash deployment toward capital expenditure.
Capacity Expansion: Delayed but on Track
DOMS has committed Rs2.5 billion in capital expenditure for fiscal 2026, with Rs2.3 billion spent through nine months. The crown jewel is the greenfield expansion at the 44-acre facility, originally slated for first-quarter fiscal 2027 commissioning. Unseasonal rains during late 2025 caused delays, but JM Financial reports “significant progress has since been made” with building completion now expected in first-quarter fiscal 2027 and commercial production starting in second-quarter fiscal 2027.
“With new capacities firing in fiscal 2027, product basket expanding and acquisitions scaling up, DOMS is looking at healthy growth,” Nuvama said.
Premium Bags: The FILA Gamble
The board approved a 50-50 joint venture with Seven SPA (part of the F.I.L.A. Group) to manufacture premium backpacks, pencil cases, and bags. DOMS will invest up to Rs75 million in the venture, which targets completion by June 2026 and will initially focus on exports for FILA’s global network while developing differentiated products for India.
“The JV is likely to be completed by first-quarter fiscal 2027 and shall start with focus on exports,” Nuvama noted. At Rs150 million in total initial investment, this isn’t a bet-the-company move—it’s a strategic option on premium bags that leverages FILA’s brand equity and global distribution. If it works, DOMS gains another growth vector. If not, the downside is contained.
Valuation: Priced in
Here’s where wealth builders must pause. Nuvama retained its BUY rating while raising the target price to Rs3,555 from Rs3,390—valuing the stock at 60 times third-quarter fiscal 2028 earnings. Yes, sixty times forward earnings for a company making pencils and diapers.
The bull case rests on sustained 18-20% revenue growth, stable-to-improving margins as new capacity ramps, successful diversification into hygiene and bags, and DOMS’ track record of consistent execution. The company’s return ratios remain healthy, and it’s generating cash even while investing heavily.
The bear case whispers about what happens when growth inevitably moderates. Consumer discretionary spending in India faces headwinds. Competition in stationery remains intense. The hygiene business, while promising, fights established giants. And at 60 times earnings, any execution stumble—delayed capacity, margin pressure, acquisition disappointment—triggers compression.
